Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 4/21/25 → 4/21/27 |
Funding
- Bicara Therapeutics Incorporated: $2.00
24-HN-42-BT(BCA101X301): A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carc
- Arnold, Susanne M (PI)